Page 49 - Read Online

Paridar et al. BCR-ABL and myelodysplastic syndrome

Table 2: Characteristics of MDS patients with BCR-ABL fusion
Hematological
No. Age/gender MDS subtype Ph+ phase/type Cytogenetic findings Outcome Ref.
findings
1 69/M RAEBt At diagnosis/P190 46, XY[3]/45, X, -y[2]/50, Hb = 8.1 Progressed to [37]
XY, +Y, -3, del5 (q12q34), WBC = 5.3 AML/died
+8, +14, add(18)(p11), Plt = 77
+22, +min[11]/idem, t(9;22)
(q34;q11)
2 64/M RAEB At diagnosis/P190 46, XY[7]/47, XY, +8, t(9;22) Hb = 7.8 Progressed to [37]
(q34;q11)[6] WBC = 6.9 AML/died
Plt = 98
3 3/M RAEBt AML late stage 46, XY, t(9;22)(q34;q11) Hb = 6.2 Progressed to [38]
transformation/P210 WBC = 4.7 AML
Hb = 47
4 54/M RA ALL transformation 46, XY, t (9;22) Hb = 8.6 Progressed to [39]
stage/P190 (q34;q11).20q- (18/20)/46, WBC = 3.2 ALL/died
XY, 20q- Plt = 142
5 78/M RAEBt At diagnosis/P190 46, XY, der (3) t(1;3) Hb = 9.8 Died in 5 months [35]
(p22;p14), del (5) (q13q33)/ WBC = 13.5
FISH revealed fusion signal Plt = 29
of BCR and ABL probes
on an apparently normal
chromosome 22
6 67/F RAEB-2 At diagnosis/ Ph+ [29/30], normal [1/30] Hb = 11.5 Complete [11]
P210(b2a2) WBC = 3.4 remission with
Plt = 111 imatinibmesylate
7 39/M RAEB AML transformation/ 46, XY, t (3;3)(y21:q26)[50] Hb = 7.1 Progressed to [40]
early stage p210 46, XY, del (l)(p22). t(3;3) WBC = 7.1 AML/died
and late stage p210 (q21: y26). -16[6] Plt = 547
and p190 46, XY, t(3;3)(q21:q26), t
(9;22) (q34:q11)[3]
8 25 months/F unclassified At diagnosis/- 46, XX, t (9;22) (q34;q11) Hb = 8.7 Died in 28 [10]
[15] WBC = 7.9 months
Plt = 39
9 20 months/F unclassified 24 months after 37-45, XX, −18[7]/46, XX[4]. Hb = 5.9 Treated with [10]
diagnosis/- nuc fish 9q34 (abl×2), 22q11 WBC = 26.3 low dose
(bcr×2) (ablcon bcr×1) Plt = 71 chemotherapy
[4/200]
10 73/M CMMoL 7 months after 46, XY, t(4;6) (p15;p12), Hb = 15.4 CML/died in 10 [41]
diagnosis/- t(9;22) (q34;q11) [10%] WBC = 18.1 months
Plt = 31
11 63/M RA During 46, XY, t(9;22) (q34;q11) Hb = 10.2 CML/died in 3 [41]
myeloproliferative [100%] WBC = 1.4 months
phase/- Plt = 165
12 66/M RAEB-2 AML transformation/ Karyotype was neg for Ph Hb = 6.2 Progressed to [42]
P190 but FISH indicate a fusion WBC = 1.7 AML/died
signal in 60% Plt = 33
13 73/M RAEB In CML 46, XY, t (9;22)/fish indicated - Progressed to [43]
transformation/P210 single Ph 98.0% CML then all
died
14 66/F RAEB At diagnosis/- 47, XX, +8, t(9;22;16) Hb = 4.4 Progressed to [44]
(q34;q11.2;q23) [4]/46, WBC = 0.9 granulocytic
XX, idem, der (12) t(12;17) Plt = 52 sarcoma skin in
(p11.2;q11.2) [7]/46, XX[9] 9 months and
died 1 month
later
15 71/M RAEB At diagnosis/- 46, XY, t(9;22) (q34;q11) Hb = 9 Progressed [44]
[20] WBC = 4000 to RAEBt in 5
Plt = 55 months and died
9 months after
diagnosis
16 59/M RAEB At diagnosis/P210 46, XY, t(9;22) (q34;q11) Hb = 9.2 Progressed to [44]
[20] WBC = 1.3 AML/treated
Plt = 78 with allogeneic
transplant
Continued...
Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ February 28, 2017 41